Definium Therapeutics unveils AI-driven advances at ASCP event in Miami Beach

Definium Therapeutics unveils AI-driven advances at ASCP event in Miami Beach
Definium spotlights AI at ASCP

Definium Therapeutics presented new developments in artificial intelligence applications for psychiatric drug development at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami Beach.

The company’s Chief Medical Officer joined leading industry experts to discuss how AI is influencing the future of mental health care. The event signaled growing momentum behind digital tools shaping the next generation of psychiatric treatments. Details on specific solutions are pending further disclosure.

Definium Therapeutics previously started patient dosing in Ascend, its second Phase 3 pivotal study for major depressive disorder, according to company disclosures. The firm also revealed pre-clinical safety results for its psychedelic therapy at the APA Annual Meeting earlier this year. These updates come as the company expands its focus to AI-driven drug development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.